Do you want to visit the AmgenPro website and leave Amgen.nl?
You are now leaving the Amgen Netherlands website and will be redirected to AmgenPro – the portal designed specifically for healthcare professionals. This website is only available in Dutch. Healthcare professionals who are authorized to prescribe medication, can create an account using their BIG number and will then gain access to all available information.
On the field of Hockey Club ’s-Hertogenbosch, the pace is high. From the sidelines, Imme — a first-team player and (paediatric) physiotherapist — shares how her life suddenly changed in the summer of 2024. Within just a few days, she lost the vision in her right eye. Not long after, she received the diagnosis: Neuromyelitis Optica Spectrum Disorder (NMOSD), a rare autoimmune disease.
“I realised something wasn’t right with my vision…”
“During a visit to the Olympic Games in Paris, my vision in my right eye deteriorated rapidly over the course of a few days,” Imme explains. “From seeing fewer contours, I ended up seeing almost nothing at all. It’s the kind of moment you don’t plan for. It happens to you. And that’s when I entered the medical process and received treatment.”
Imme is used to focusing on what *is* possible. That mindset is reflected in her sport, but also in her work — helping people recover, step by step. And it was exactly that approach that helped her when she became a patient herself.
What is NMOSD?
NMOSD resembles multiple sclerosis (MS), but it is a different disease with its own course and treatment. It is a rare autoimmune condition in which inflammation occurs in the central nervous system, particularly affecting the optic nerve and the spinal cord. This can lead to problems with vision, sensation and movement. In the Netherlands, an estimated 200 people are living with NMOSD1.
Watch Imme’s video and hear her story here:
In this video, Imme shares her personal story about being diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD), a rare autoimmune disease. From the stadium of Hockey Club ’s-Hertogenbosch, she explains how her vision suddenly changed and how she is learning to adapt to her new reality step by step.
My name is Imme, I’m 28 years old. I play field hockey for HC ’s-Hertogenbosch Women’s First Team.
Last summer, I was diagnosed with NMOSD. Over the course of a few days that summer, my vision in my right eye deteriorated rapidly. I remember the day clearly. On August 6, I went to the Olympic Games. I believe it was the day of the semifinal. And I suddenly thought, “It really feels like I’m not seeing as well.”
So I covered my left eye with my hand. That’s when I realized, “I’m definitely seeing less.” It went from blurred outlines to barely seeing anything at all. After that, I found myself navigating the medical system.
Today, I don’t experience limitations in my daily life as a physiotherapist, a pediatric physiotherapist, and as a player for ’s-Hertogenbosch Women’s First Team.
In the time leading up to it, everything happened so fast that I didn’t fully process what was happening to me. That realization really came later, through the reactions of my family, friends, and teammates.
I think it’s important to share my story because it’s a rare condition, and I hope I can help others by speaking about it. Even with this condition, you can still live a happy and fulfilling life.
My advice is: consult your doctor if you experience symptoms similar to the ones I had.
Disclaimer
This page is intended as a personal experience story and general information. It does not constitute medical advice. If you experience symptoms, please contact a healthcare professional.
This patient was not treated with an Amgen medicine.
By selecting the Yes option, leaving Amgen.nl option you understand that you are leaving the corporate page of Amgen nl and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen nl is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in nl. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
By selecting the Yes option, leaving Amgen.nl option you understand that you are leaving the corporate page of Amgen nl and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen nl is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in nl. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
